Corbus Pharmaceuticals Holdings (CRBP) Accumulated Expenses (2013 - 2025)

Corbus Pharmaceuticals Holdings' Accumulated Expenses history runs 13 years deep, the most recent figure standing at $16.8 million for Q4 2025.

• On a quarterly basis, Accumulated Expenses rose 640.07% year-over-year to $16.8 million in Q4 2025; TTM through Dec 2025 was $16.8 million, a 640.07% increase from a year earlier, with the FY2025 full-year figure at $16.8 million, up 640.07% from the prior year.
• Accumulated Expenses improved to $16.8 million in Q4 2025 per CRBP's latest filing, from $2.4 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $16.8 million in Q4 2025 and bottomed at $965542.0 in Q3 2022.
• The 5-year median for Accumulated Expenses is $2.3 million (2024), against an average of $4.8 million.
• Across the five-year window, Accumulated Expenses surged 681.51% in 2023 and sank 89.37% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $2.7 million in 2021, then dropped by 18.06% to $2.2 million in 2022, then soared by 395.74% to $11.0 million in 2023, then plunged by 79.37% to $2.3 million in 2024, then soared by 640.07% to $16.8 million in 2025.
• Per Business Quant, the three latest CRBP Accumulated Expenses figures stand at $16.8 million (Q4 2025), $2.4 million (Q3 2025), and $1.9 million (Q2 2025).